ELOX

Eloxx Pharmaceuticals Inc

17.51

Aug 12 • 2:37 PM ET -1.67 (-8.71%)

Healthcare Biotechnology USA Nano NASD

Today, 8:15 AMEloxx Pharmaceuticals Q2 2026: non-GAAP EPS -$0.66 on zero revenue, $62M cash funds operations into mid-2028

Peers: BDRX SCNI VBIO BBLG MBRX SLXN AZTR GNPX CLDI VRAX

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	0.73M
Enterprise Value	-5.64M
Income	-
Sales	-
Book/sh	-16.44
Cash/sh	152.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Dec 11, 1998

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	0.11
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.48
Current Ratio	0.48
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	75.85% 61.60%
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	97.33%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	- -

Insider Own	46.25%
Insider Trans	0.00%
Inst Own	-
Inst Trans	20.81%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	18.43%
SMA50	38.24%
SMA200	391.31%
Trades

Shs Outstand	0.46M
Shs Float	-
Short Float	-
Short Ratio	0.34
Short Interest	0.02M
52W High	19.96 -12.27%
52W Low	- -
Volatility	11.21% 14.54%
ATR (14)	2.09
RSI (14)	62.18
Beta	-147765.48
Rel Volume	1.04
Avg Volume	49.07K
Volume	40,571

Perf Week	-2.07%
Perf Month	55.51%
Perf Quarter	75700.87%
Perf Half Y	1591718.16%
Perf YTD	1591718.21%
Perf Year	159181725.00%
Perf 3Y	-66.49%
Perf 5Y	-96.99%
Perf 10Y	-98.89%
Recom	1.00
Target Price	41.50
Prev Close	19.18
Price	17.51
Change %	-8.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-26	Initiated	Guggenheim	Buy	$43

Today 06:00AM

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

(PR Newswire) -8.71%

Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. It focuses on the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Arlington, MA.

PresidentMr. Sumit Aggarwal M.B.A.

Interim Chief Financial OfficerMr. Daniel E. Geffken M.B.A.

VP & Head of Corporate DevelopmentMr. John Woolford

Chief Medical OfficerDr. Ali Hariri M.D.

VP & Head of Discovery SciencesDr. Roger Clark

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELOX

Eloxx Pharmaceuticals Inc

Upgrade your Finviz experience